Disease · MONDO_0005083
Trials495
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.
1 to 20 of 495
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02409667 | Plaque Psoriasis Efficacy and Safety With Secukinumab | Phase 3 | 16,487 | 2019-05-13 | Plaque Psoriasis | SECUKINUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01708629 | Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects | Phase 3 | 1,881 | 2020-01-03 | Plaque Psoriasis | BRODALUMAB, USTEKINUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02752776 | A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. | Phase 4 | 1,660 | 2019-09-25 | Plaque Psoriasis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01358578 | Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis | Phase 3 | 1,306 | 2015-09-23 | Chronic Plaque Psoriasis | ETANERCEPT, SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02513550 | A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis | Phase 3 | 1,257 | 2018-04-18 | Plaque Psoriasis | IXEKIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01544595 | Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab | Phase 3 | 1,147 | 2018-12-20 | Moderate to Severe Plaque-type Psoriasis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02826603 | Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis | Phase 3 | 1,114 | 2019-07-09 | Plaque Psoriasis | SECUKINUMAB, USTEKINUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01729754 | A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) | Phase 3 | 1,090 | 2018-06-27 | Plaque Psoriasis | TILDRAKIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00760669 | An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants | 1,061 | 2013-08-12 | Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03573323 | A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis | Phase 4 | 1,027 | 2020-07-28 | Plaque Psoriasis | GUSELKUMAB, IXEKIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02404350 | Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis | Phase 3 | 997 | 2019-06-28 | Psoriatic Arthritis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01406938 | Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens | Phase 3 | 967 | 2015-05-19 | Moderate to Severe Plaque-type Psoriasis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03818035 | A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis | Phase 3 | 880 | 2023-05-10 | Psoriasis | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02886702 | A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis | Phase 3 | 855 | 2018-08-29 | Plaque Psoriasis | TAZAROTENE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01194219 | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis | Phase 3 | 844 | 2014-11-05 | Plaque Psoriasis | APREMILAST | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01722331 | A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) | Phase 3 | 772 | 2018-06-13 | Plaque Psoriasis | TILDRAKIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00267969 | A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis | Phase 3 | 766 | 2012-08-24 | Psoriasis | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04053387 | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) | Phase 3 | 763 | 2022-08-08 | Plaque Psoriasis | TAPINAROF | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00245960 | Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis | Phase 4 | 752 | 2009-05-27 | Psoriatic Arthritis | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03536884 | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | 743 | 2022-10-10 | Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | BIMEKIZUMAB, SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005083/trials